Trials / Completed
CompletedNCT00947882
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A Dose-Finding, Multi-Centre, Double-Blind, Randomised, Parallel, Placebo-Controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 404 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Mannitol 50 mg/mL solution |
| DRUG | Degarelix 10 mg | 10 mg degarelix, 40 mg/mL solution |
| DRUG | Degarelix 20 mg | 20 mg degarelix, 40 mg/mL solution |
| DRUG | Degarelix 30 mg | 30 mg degarelix, 40 mg/mL solution |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-03-01
- Completion
- 2011-06-01
- First posted
- 2009-07-28
- Last updated
- 2015-06-08
- Results posted
- 2015-05-14
Locations
47 sites across 6 countries: United States, Belgium, Canada, Czechia, Italy, Poland
Source: ClinicalTrials.gov record NCT00947882. Inclusion in this directory is not an endorsement.